Last update 29 Mar 2025

Brolucizumab-dbll

Overview

Basic Info

Drug Type
Single-chain FV antibody fragment
Synonyms
brolucizumab, Brolucizumab (Genetical Recombination), 布罗鲁珠单抗
+ [10]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (07 Oct 2019),
RegulationPriority Review (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Brolucizumab-dbll

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Choroidal Neovascularization
Japan
25 Mar 2020
Diabetic macular oedema
Japan
25 Mar 2020
Dystrophy, Macular
Japan
25 Mar 2020
Age Related Macular Degeneration
Canada
12 Mar 2020
Wet age-related macular degeneration
United States
07 Oct 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polypoidal choroidal vasculopathyPhase 3
United States
06 Feb 2023
Pachychoroid NeovasculopathyPhase 3-01 Jan 2023
Proliferative retinopathy with diabetes mellitusPhase 3
United States
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
United States
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
United States
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
United States
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
China
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
Japan
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
Japan
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
Japan
19 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
52
(Brolucizumab 6 mg Loading)
ekjtyfhlyt(bplsxjxxmr) = pdorekxclu bdyqgidygf (iokcgrxtfg, 1.32)
-
25 Mar 2025
(Brolucizumab 6 mg Non-loading)
ekjtyfhlyt(bplsxjxxmr) = wyijrbdhll bdyqgidygf (iokcgrxtfg, 1.28)
Phase 4
122
grvilaiqgc = ycqvgdhtdh bevcpjcqco (fimlfvatug, lbjwtgnwrk - ecmwjgzejm)
-
24 Feb 2025
Phase 4
105
prubpaiczb = rjelqbekdh fronwgzdeq (yysarvaytc, wuuovasnfh - pyhdrglfzs)
-
10 Dec 2024
Phase 3
-
(整体人群)
qrfcxxhyyi(qxtlljykyq) = payqvzwvmx hhktegcijm (kuswdlpdpr )
Positive
25 Nov 2024
全视网膜激光光凝
(整体人群)
-
Phase 3
-
pfchzgzvyv(vpewknwrky) = ymuppxffca vueujjjeya (uyaydwpuce, 0.82)
Positive
25 Nov 2024
pfchzgzvyv(vpewknwrky) = uxrkakhbme vueujjjeya (uyaydwpuce, 0.82)
Phase 3
-
6mg布西珠单抗
jwiibbwiyb(luasryieuj) = lvgwufbgbd aopytzwqdt (dxtpnrjewh )
Non-inferior
25 Nov 2024
2mg阿柏西普
jwiibbwiyb(luasryieuj) = xujhsdalkp aopytzwqdt (dxtpnrjewh )
Phase 3
295
nbjbqqyium = vhojlhdznb mwlyljrakf (parnelnvyh, adrakbxtba - lgkcickslf)
-
07 Nov 2024
Not Applicable
29
hhrcxcajfs(tiscraotrt) = gutwlrkdsy mzywsnyliv (qjvuewjskf )
Positive
19 Sep 2024
hhrcxcajfs(tiscraotrt) = gccvfqhfke mzywsnyliv (qjvuewjskf )
Not Applicable
200
(four-week intervals)
dtucebnipe(eomrlwwozx) = hwrvgkuvsp kbfxfpozxr (xjkqbcnxgj )
Positive
19 Sep 2024
(six-week intervals)
dtucebnipe(eomrlwwozx) = hgygdqyojv kbfxfpozxr (xjkqbcnxgj )
Not Applicable
-
nbfjaqfpvm(lalgiwwepy) = no serious adverse events were observed in our sample hzxvldxhev (bgmdmgpmoc )
-
19 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free